In 2007 the company started developing
biopharmaceuticals. In May 2012 Synthon announced that it bought the
Biolex LEX System for manufacturing biopharmaceuticals in
Lemna. The sale also included two
preclinical biologics made with the LEX System, BLX-301, a humanized and glyco-optimized anti-
CD20 antibody for
non-Hodgkin's B-cell lymphoma and other
B-cell malignancies and BLX-155, a direct-acting
thrombolytic. The financial terms of the sale were not disclosed. == See also ==